login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Avinger’s Ocelot catheter is CE marked


Thursday, 29 Sep 2011 11:21

Avinger has received CE mark approval for Ocelot ― a peripheral catheter system used with real-time Optical Coherence Tomography (OCT) for the treatment of peripheral artery disease.


According to Avinger, medical professionals, for the first time ever, will have access to a therapeutic device that incorporates real time intravascular guidance by using Ocelot’s Lightbox console as an adjunct to fluoroscopy.


“Ocelot CE mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I have been working on uniting intravascular guidance with therapeutic products for 30 years and I am humbled that we have been able to achieve this at Avinger,” said John B Simpson, Avinger’s founder and CEO.


Avinger is currently enrolling patients in the VISTA study ― a single-centre, non-randomised registry designed to evaluate the safety and efficacy of Ocelot in patients with peripheral artery disease. The registry is being developed in Paraguay, with Adrian Ebner of Sanitorio Italiano in Asunción, as the principal investigator.


European comercialisation of Ocelot has already begun. The first three commercial cases are scheduled to be performed in Italy and Germany in late September and early October.

 




Add New Comment

Most popular


DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients
Friday, 29 Aug 2014
The multicentre, 800-patient study also demonstrated that directional atherectomy was non-inferior for treating peripheral arterial disease in patients with diabetes compared with those without ... DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients

First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam) 1%
Tuesday, 12 Aug 2014
The first varicose vein patient has been treated with Varithena, the only FDA-approved foam for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities ... First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam) 1%

Arterial embolization works to alleviate knee pain in mild to moderate osteoarthritis
Monday, 21 Jul 2014
A small study conducted in Japan, published in CardioVascular and Interventional Radiology in July 2014, demonstrates that transcatheter arterial embolization is feasible and that it rapidly relieves ... Arterial embolization works to alleviate knee pain in mild to moderate osteoarthritis

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Is all heat the same and does catheter design matter?
Wednesday, 13 Aug 2014
Mark S Whiteley writes that it is essential that every doctor practising varicose vein surgery has a good understanding of the principles of endovenous thermoablation. Is all heat the same and does catheter design matter?

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions